Company news: IMS, SDI and inVentiv Health

Share this article:
IMS said global spending on medicine will slow over the next five years to 3%-6% reflecting slowing growth in developed markets due to patent losses and policy changes – compared to a CAGR of 6.2% for the past five years. The data firm cited lower spending growth in the US, the continuing impact of patent expiries and belt-tightening as factors in the slowdown, offset by continued strong growth in emerging markets like Brazil, Russia, India and China, whose collective spending will become the second largest behind the US, surpassing Europe as a profit center for pharmas. 
 
SDI's Pollen.com launched an allergy alert app for Ford's dashboard SYNC system, aimed at reducing driver distractions. The app offers one-day alerts and four-day location-specific forecasts on allergy, asthma, cold and cough, along with UV sensitivity. 
 
InVentiv Health is buying contract research organization PharmaNet Development Group. It's the firm's second CRO investment since January.
Share this article:

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.